Hematopoiesis News Volume 14.32 | Aug 15 2023

    By
    Jamie Kang
    -
    0
    13







    2023-08-15 | HN 14.32


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.32 – 15 August, 2023
    TOP STORY

    In Vivo Screening Characterizes Chromatin Factor Functions during Normal and Malignant Hematopoiesis

    Scientists combined bulk ex vivo and single-cell in vivo CRISPR screens to characterize the role of chromatin factor families in hematopoiesis.
    [Nature Genetics]

    Full Article
    Return to your lab safely and efficiently with these guides and resources so that you can focus more on moving your research goals forward.
    PUBLICATIONSRanked by the impact factor of the journal

    Loss of Endothelial Membrane KITLigand Affects Systemic KIT Ligand Levels but Not Bone Marrow Hematopoietic Stem Cells

    Investigators confirmed that upon deletion of both the soluble and membrane-bound form of endothelial-derived KIT Ligand hematopoietic stem cells were reduced in mouse bone marrow.
    [Blood]

    Abstract

    MTH1 Protects Platelet Mitochondria from Oxidative Damage and Regulates Platelet Function and Thrombosis

    Scientists showed human MutT homolog 1 (MTH1) expression in platelets and its deficiency impaired hemostasis and arterial/venous thrombosis in vivo.
    [Nature Communications]

    Full Article

    Rescue of Alzheimer’s Disease Phenotype in a Mouse Model by Transplantation of Wild-Type Hematopoietic Stem and Progenitor Cells

    Investigators showed that single systemic wild-type hematopoietic stem and progenitor cell transplantation rescued the Alzheimer’s disease phenotype in 5xFAD mice and that transplantation may prevent microglia activation.
    [Cell Reports]

    Full ArticleGraphical Abstract

    PRMT1 Methylation of Wtap Promotes Multiple Myeloma Tumorigenesis by Activating Oxidative Phosphorylation via m6A Modification of NDUFS6

    Researchers found that protein arginine methyltransferase 1 (PRMT1) was highly expressed in multiple myeloma (MM) patients, which was positively correlated with MM stages. They further showed that silencing PRMT1 inhibited MM proliferation and tumorigenesis in vitro and in vivo.
    [Cell Death & Disease]

    Full Article

    A Myc-Controlled Redox Switch Protects B Lymphoma Cells from EGR1-Dependent Apoptosis

    Scientists reported that high MYC expression stimulated proliferation and protected B lymphoma cells from apoptosis under normal oxidative stress levels, and that compounds including N-acetylcysteine and vitamin C induce apoptosis by reducing oxidative stress.
    [Scientific Reports]

    Full ArticleGraphical Abstract

    Characterizing the Role of Phlda3 in the Development of Acute Toxicity and Malignant Transformation of Hematopoietic Cells Induced by Total-Body Irradiation in Mice

    Using isogenic cell lines and genetically engineered mouse models, investigators showed that radiation induces Phlda3 in human leukemia cells and mouse normal hematopoietic cells in a p53-dependent manner.
    [Scientific Reports]

    Full Article

    Use, Variability, and Justification of Eligibility Criteria for Phase II and III Clinical Trials in Acute Leukemia

    Researchers analyzed criteria and drug safety data for front-line phase II and/or III acute leukemia trials with start dates 1/1/2010-12/31/2019 registered on ClinicalTrials.gov.
    [Haematologica]

    Abstract

    High Rate of Durable Responses with Undetectable Minimal Residual Disease with Front-Line Venetoclax and Rituximab in Young, Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biological Profile: Results of the Gimema Phase II LLC1518 – Ve

    The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of front-line, fixed-duration venetoclax and rituximab in combination in young, fit patients with chronic lymphocytic leukemia and unmutated IGHV and/or TP53 disruption.
    [Haematologica]

    Abstract
    Virtual Conference Exhibition: Pluripotent Stem Cells
    REVIEWS

    Should Autologous Hematopoietic Stem Cell Transplantation Be Offered as a First-Line Disease Modifying Therapy to Patients with Multiple Sclerosis?

    The available evidence on the potential role of autologous hematopoietic stem cell transplantation (AHSCT) as first-line treatment in aggressive multiple sclerosis (MS) and the rationale for its early use is summarized.
    [Multiple Sclerosis And Related Disorders]

    Full Article

    INDUSTRY AND POLICY NEWS

    Research on ISS to Determine If Stem Cell Production in Space Can Improve Cancer Treatments on Earth

    A Commercial Resupply Services mission to the International Space Station (ISS) launched carrying diverse sets of research projects to determine the benefits of working in microgravity. One of the projects will determine if stem cell production in space can improve cancer treatments for patients on earth.
    [Inside Precision Medicine]

    Editorial
    FEATURED EVENT

    89th Harden Conference – Proteoglycans: Matrix Master Regulators 2023

    September 4 – 7, 2023
    Surrey, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Professor – Leukemia/Lymphoma Program Leader

    University of Colorado – Aurora, Colorado, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    Postdoctoral Project Research Scientist – Signaling and Structural Laboratory

    Francis Crick Institute – London, England, United Kingdom

    Postdoctoral Position – Proteostasis, Hematopoiesis, and AML

    National Institutes of Health – Bethesda, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter

    Brought to you by